{"id":"W4406822184","doi":"10.1093/bjd/ljaf032","title":"Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period","year":2025,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Cilag; Manchester Biomedical Research Centre; Sanofi Genzyme; Genentech; Medac; L'Oreal USA; Bausch Health; Celltrion; Astellas Pharma; National Institute for Health and Care Research; Pfizer; Biogen; Incyte; Castle Biosciences; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Meiji Seika Pharma; Les Laboratories Pierre Fabre; Galderma; LEO Pharma; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Secukinumab; Medicine; Psoriasis; Adverse effect; Psoriasis Area and Severity Index; Interleukin 17; Plaque psoriasis; Open label; Dosing; Clinical trial; Internal medicine; Dermatology; Psoriatic arthritis; Cytokine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004454645,0.001381604,0.003550891,0.0004403214,0.0008208675,0.001514911,0.00097226,0.001952397,0.002967228],"category_scores_gemma":[0.002163643,0.0006707263,0.002879779,0.0005561098,0.001015382,0.001462962,0.0005741682,0.004608172,0.0009625312],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009563531,"about_ca_system_score_gemma":0.001297063,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007659818,"about_ca_topic_score_gemma":0.001282724,"domain_scores_codex":[0.9985682,0.0006346615,0.00008179078,0.0002396258,0.0001868915,0.0002887799],"domain_scores_gemma":[0.9981061,0.0002827882,0.0005700125,0.0002072374,0.0001614684,0.0006723111],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9310299,0.02257561,0.004590534,0.0004740123,0.001502197,0.00008450267,0.0001072347,0.0004461131,0.005606483,0.00008930208,0.00178902,0.03170509],"study_design_scores_gemma":[0.6668933,0.2927735,0.03371471,0.00008078339,0.001775585,0.0002282728,0.00004650393,0.0006278587,0.001470679,0.0002342403,0.002111515,0.00004310692],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855715,0.009199642,0.0004416666,0.0005637023,0.000159875,0.001244539,0.001085411,0.00008772961,0.001645915],"genre_scores_gemma":[0.9884293,0.002998091,0.000827701,0.001203665,0.0004346903,0.002051646,0.002185332,0.00002813742,0.001841499],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004454645,"threshold_uncertainty_score":0.02355868,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02186603706440261,"score_gpt":0.2762265906013623,"score_spread":0.2543605535369597,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}